Novyra Pharmachem Limited has changed its official email address with immediate effect. The company notified BSE Limited of the update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The new official email ID is novyrapharmachemlimited@gmail.com . This replaces the previous address, bansisonstea@gmail.com . All future official correspondences and investor grievances should be directed to the new address.

Contact details update

The company requested BSE to update the contact details on its portals. The change was communicated by Anilkumar Mohanbhai Amreliya, Director of the company.

Novyra Pharmachem Limited was formerly known as Bansisons Tea Industries Ltd. The name change reflects the company's current identity.

Bansisons Tea Industries Ltd bansisons tea industries has updated its official website address to reflect its current corporate identity as Novyra Pharmachem Limited. The company announced on August 4, 2026, that its digital disclosures and investor information are now hosted at www.novyrapharmachemltd.com , replacing the former domain www.bansisonstea.com . This change ensures that shareholders and stakeholders can access material information through a platform that accurately represents the company’s present name and business focus.

The intimation was submitted to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that all statutory disclosures required under Regulation 46 of the same regulations are now available on the new website. The move is part of the company’s broader transition following its name change from Bansisons Tea Industries Ltd to Novyra Pharmachem Limited.

Website Transition Details

The company provided specific details regarding the change in digital infrastructure:

Anil M. Amreliya, Director of Novyra Pharmachem Limited, signed the intimation filed with the exchange. The company requested BSE Limited to update its records accordingly to ensure that investors are directed to the correct source for official communications.

Regulatory Compliance

Under Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities must host specific disclosures on their websites, including financial results, annual reports, and other material events. By migrating these disclosures to the new domain, Novyra Pharmachem Limited maintains its compliance obligations without disruption. The old website address is no longer the primary channel for such information.

What the Numbers Show

While this announcement does not contain financial metrics, it signals a structural alignment between the company’s legal identity and its public-facing communications. The shift from a tea-industry-focused domain to one reflecting "Pharmachem" underscores the strategic pivot implied by the name change. Investors should note that all future regulatory filings and investor relations materials will be accessible exclusively through the new portal, ensuring consistency in information dissemination.